UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2004
Commission file number 1-3433
THE DOW CHEMICAL COMPANY
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation or organization) |
38-1285128 (I.R.S. Employer Identification No.) |
2030 DOW CENTER, MIDLAND, MICHIGAN 48674
(Address of principal executive offices) (Zip Code)
989-636-1000
(Registrant's telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o
| Class |
|
Outstanding at June 30, 2004 |
||
|---|---|---|---|---|
| Common Stock, par value $2.50 per share | 939,431,901 shares |
The Dow Chemical Company
Table of Contents
| |
PAGE |
|||
|---|---|---|---|---|
| PART IFINANCIAL INFORMATION | ||||
Item 1. Financial Statements |
3 |
|||
Consolidated Statements of Income |
3 |
|||
Consolidated Balance Sheets |
4 |
|||
Consolidated Statements of Cash Flows |
5 |
|||
Consolidated Statements of Comprehensive Income |
5 |
|||
Notes to the Consolidated Financial Statements |
6 |
|||
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations |
24 |
|||
Disclosure Regarding Forward-Looking Information |
24 |
|||
Results of Operations |
24 |
|||
Changes in Financial Condition |
32 |
|||
Other Matters |
34 |
|||
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
40 |
|||
Item 4. Controls and Procedures |
41 |
|||
PART IIOTHER INFORMATION |
||||
Item 1. Legal Proceedings |
42 |
|||
Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities |
42 |
|||
Item 4. Submission of Matters to a Vote of Security Holders |
43 |
|||
Item 6. Exhibits and Reports on Form 8-K |
44 |
|||
SIGNATURE |
46 |
|||
EXHIBIT INDEX |
47 |
|||
2
PART IFINANCIAL INFORMATION
Item 1. Financial Statements
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Income
| |
Three Months Ended |
Six Months Ended |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In millions, except per share amounts (Unaudited) |
June 30, 2004 |
June 30, 2003 |
June 30, 2004 |
June 30, 2003 |
||||||||||
| Net Sales | $ | 9,844 | $ | 8,242 | $ | 19,153 | $ | 16,323 | ||||||
| Cost of sales | 8,345 | 6,970 | 16,252 | 14,133 | ||||||||||
| Research and development expenses | 262 | 246 | 513 | 483 | ||||||||||
| Selling, general and administrative expenses | 347 | 354 | 710 | 709 | ||||||||||
| Amortization of intangibles | 16 | 15 | 45 | 30 | ||||||||||
| Restructuring net gain | 20 | | 20 | | ||||||||||
| Equity in earnings of nonconsolidated affiliates | 254 | 90 | 394 | 129 | ||||||||||
| Sundry income (expense)net | 13 | 52 | (15 | ) | 46 | |||||||||
| Interest income | 21 | 18 | 39 | 38 | ||||||||||
| Interest expense and amortization of debt discount | 182 | 207 | 368 | 422 | ||||||||||
| Income before Income Taxes and Minority Interests | 1,000 | 610 | 1,703 | 759 | ||||||||||
| Provision for income taxes | 284 | 186 | 488 | 233 | ||||||||||
| Minority interests' share in income | 31 | 31 | 61 | 48 | ||||||||||
| Income before Cumulative Effect of Change in Accounting Principle | 685 | 393 | 1,154 | 478 | ||||||||||
| Cumulative effect of change in accounting principle | | | | (9 | ) | |||||||||
| Net Income Available for Common Stockholders | $ | 685 | $ | 393 | $ | 1,154 | $ | 469 | ||||||
| Share Data | ||||||||||||||
| Earnings before cumulative effect of change in accounting principle per common sharebasic |
$ | 0.73 | $ | 0.43 | $ | 1.23 | $ | 0.52 | ||||||
| Earnings per common sharebasic | $ | 0.73 | $ | 0.43 | $ | 1.23 | $ | 0.51 | ||||||
| Earnings before cumulative effect of change in accounting principle per common sharediluted |
$ | 0.72 | $ | 0.43 | $ | 1.22 | $ | 0.52 | ||||||
| Earnings per common sharediluted | $ | 0.72 | $ | 0.43 | $ | 1.22 | $ | 0.51 | ||||||
| Common stock dividends declared per share of common stock | $ | 0.335 | $ | 0.335 | $ | 0.67 | $ | 0.67 | ||||||
| Weighted-average common shares outstandingbasic | 938.0 | 917.3 | 934.9 | 916.0 | ||||||||||
| Weighted-average common shares outstandingdiluted | 947.9 | 921.9 | 945.8 | 921.8 | ||||||||||
| Depreciation | $ | 458 | $ | 426 | $ | 920 | $ | 859 | ||||||
| Capital Expenditures | $ | 329 | $ | 272 | $ | 530 | $ | 495 | ||||||
See Notes to the Consolidated Financial Statements.
3
The Dow Chemical Company and Subsidiaries
Consolidated Balance Sheets
| In millions (Unaudited) |
June 30, 2004 |
Dec. 31, 2003 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and cash equivalents | $ | 2,294 | $ | 2,392 | |||||
| Marketable securities and interest-bearing deposits | 43 | 42 | |||||||
| Accounts and notes receivable: | |||||||||
| Trade (net of allowance for doubtful receivables2004: $120; 2003: $118) | 4,472 | 3,574 | |||||||
| Other | 2,110 | 2,246 | |||||||
| Inventories | 4,360 | 4,050 | |||||||
| Deferred income tax assetscurrent | 299 | 698 | |||||||
| Total current assets | 13,578 | 13,002 | |||||||
| Investments | |||||||||
| Investment in nonconsolidated affiliates | 2,242 | 1,878 | |||||||
| Other investments | 2,006 | 1,971 | |||||||
| Noncurrent receivables | 213 | 230 | |||||||
| Total investments | 4,461 | 4,079 | |||||||
| Property | |||||||||
| Property | 40,271 | 40,812 | |||||||
| Less accumulated depreciation | 26,723 | 26,595 | |||||||
| Net property | 13,548 | 14,217 | |||||||
| Other Assets | |||||||||
| Goodwill | 3,150 | 3,226 | |||||||
| Other intangible assets (net of accumulated amortization2004: $443; 2003: $406) | 562 | 579 | |||||||
| Deferred income tax assetsnoncurrent | 4,287 | 4,113 | |||||||
| Asbestos-related insurance receivablesnoncurrent | 1,086 | 1,176 | |||||||
| Deferred charges and other assets | 1,512 | 1,499 | |||||||
| Total other assets | 10,597 | 10,593 | |||||||
| Total Assets | $ | 42,184 | $ | 41,891 | |||||
| Liabilities and Stockholders' Equity | |||||||||
| Current Liabilities | |||||||||
| Notes payable | $ | 240 | $ | 258 | |||||
| Long-term debt due within one year | 104 | 1,088 | |||||||
| Accounts payable: | |||||||||
| Trade | 3,068 | 2,843 | |||||||
| Other | 2,328 | 2,041 | |||||||
| Income taxes payable | 236 | 212 | |||||||
| Deferred income tax liabilitiescurrent | 245 | 241 | |||||||
| Dividends payable | 336 | 331 | |||||||
| Accrued and other current liabilities | 2,343 | 2,520 | |||||||
| Total current liabilities | 8,900 | 9,534 | |||||||
| Long-Term Debt | 12,241 | 11,763 | |||||||
| Other Noncurrent Liabilities | |||||||||
| Deferred income tax liabilitiesnoncurrent | 1,125 | 1,124 | |||||||
| Pension and other postretirement benefitsnoncurrent | 3,620 | 3,572 | |||||||
| Asbestos-related liabilitiesnoncurrent | 1,696 | 1,791 | |||||||
| Other noncurrent obligations | 3,299 | 3,556 | |||||||
| Total other noncurrent liabilities | 9,740 | 10,043 | |||||||
| Minority Interest in Subsidiaries | 405 | 376 | |||||||
| Preferred Securities of Subsidiaries | 1,000 | 1,000 | |||||||
| Stockholders' Equity | |||||||||
| Common stock | 2,453 | 2,453 | |||||||
| Additional paid-in capital | 83 | 8 | |||||||
| Unearned ESOP shares | (27 | ) | (30 | ) | |||||
| Retained earnings | 10,519 | 9,994 | |||||||
| Accumulated other comprehensive loss | (1,726 | ) | (1,491 | ) | |||||
| Treasury stock at cost | (1,404 | ) | (1,759 | ) | |||||
| Net stockholders' equity | 9,898 | 9,175 | |||||||
| Total Liabilities and Stockholders' Equity | $ | 42,184 | $ | 41,891 | |||||
See Notes to the Consolidated Financial Statements.
4
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Cash Flows
| |
|
Six Months Ended |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| In millions (Unaudited) |
June 30, 2004 |
June 30, 2003 |
|||||||
| Operating Activities | Income before cumulative effect of change in accounting principle | $ | 1,154 | $ | 478 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||||
| Depreciation and amortization | 1,016 | 935 | |||||||
| Provision for deferred income tax | 219 | 54 | |||||||
| Earnings/losses of nonconsolidated affiliates in excess of dividends received |
(236 | ) | (45 | ) | |||||
| Minority interests' share in income | 61 | 48 | |||||||
| Net loss on sales on consolidated companies | | 3 | |||||||
| Net gain on sales of investments | (13 | ) | (16 | ) | |||||
| Net gain on sales of property and businesses | (11 | ) | (24 | ) | |||||
| Other net (gain) loss | 62 | (24 | ) | ||||||
| Net (gain) loss on sale of nonconsolidated affiliates | (17 | ) | 1 | ||||||
| Net gain on asset divestitures related to formation of nonconsolidated affiliates |
(563 | ) | | ||||||
| Restructuring charges | 496 | | |||||||
| Tax benefitnonqualified stock option exercises | 41 | 13 | |||||||
| Changes in assets and liabilities that provided (used) cash: | |||||||||
| Accounts and notes receivable | (893 | ) | (361 | ) | |||||
| Inventories | (336 | ) | (78 | ) | |||||
| Accounts payable | 584 | (41 | ) | ||||||
| Noncurrent receivables | 17 | 271 | |||||||
| Other assets and liabilities | (862 | ) | 448 | ||||||
| Cash provided by operating activities | 719 | 1,662 | |||||||
| Investing Activities | Capital expenditures | (530 | ) | (495 | ) | ||||
| Proceeds from sales of property and businesses | 27 | 83 | |||||||
| Acquisition of business | (149 | ) | | ||||||
| Investments in consolidated companies | | (69 | ) | ||||||
| Investments in nonconsolidated affiliates | (56 | ) | (48 | ) | |||||
| Distribution from nonconsolidated affiliate | 3 | | |||||||
| Proceeds from sale of nonconsolidated affiliates | 33 | 8 | |||||||
| Proceeds from asset divestitures related to formation of nonconsolidated affiliates |
845 | | |||||||
| Purchases of investments | (898 | ) | (936 | ) | |||||
| Proceeds from sales and maturities of investments | 806 | 886 | |||||||
| Cash provided by (used in) investing activities | 81 | (571 | ) | ||||||
| Financing Activities | Changes in short-term notes payable | (100 | ) | (8 | ) | ||||
| Payments on long-term debt | (1,075 | ) | (594 | ) | |||||
| Proceeds from issuance of long-term debt | 618 | 833 | |||||||
| Purchases of treasury stock | (7 | ) | (4 | ) | |||||
| Proceeds from sales of common stock | 325 | 96 | |||||||
| Distributions to minority interests | (32 | ) | (38 | ) | |||||
| Dividends paid to stockholders | (623 | ) | (612 | ) | |||||
| Cash used in financing activities | (894 | ) | (327 | ) | |||||
| Effect of Exchange Rate Changes on Cash | (4 | ) | 28 | ||||||
| Summary | Increase (Decrease) in cash and cash equivalents | (98 | ) | 792 | |||||
| Cash and cash equivalents at beginning of year | 2,392 | 1,484 | |||||||
| Cash and cash equivalents at end of period | $ | 2,294 | $ | 2,276 | |||||
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Comprehensive Income
| |
Three Months Ended |
Six Months Ended |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In millions (Unaudited) |
June 30, 2004 |
June 30, 2003 |
June 30, 2004 |
June 30, 2003 |
||||||||||
| Net Income Available for Common Stockholders | $ | 685 | $ | 393 | $ | 1,154 | $ | 469 | ||||||
| Other Comprehensive Income (Loss), Net of Tax | ||||||||||||||
| Net unrealized gains (losses) on investments | (34 | ) | 39 | (24 | ) | 32 | ||||||||
| Translation adjustments | (81 | ) | 80 | (223 | ) | 185 | ||||||||
| Minimum pension liability adjustments | (17 | ) | | (16 | ) | (3 | ) | |||||||
| Net gains on cash flow hedging derivative instruments | 35 | 18 | 28 | 2 | ||||||||||
| Total other comprehensive income (loss) | (97 | ) | 137 | (235 | ) | 216 | ||||||||
| Comprehensive Income | $ | 588 | $ | 530 | $ | 919 | $ | 685 | ||||||
See Notes to the Consolidated Financial Statements.
5
The Dow Chemical Company and Subsidiaries
Notes to the Consolidated Financial Statements
(Unaudited)
NOTE ACONSOLIDATED FINANCIAL STATEMENTS
The unaudited interim consolidated financial statements of The Dow Chemical Company and its subsidiaries ("Dow" or the "Company") were prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and reflect all adjustments (consisting of normal recurring accruals) which, in the opinion of management, are considered necessary for a fair presentation of the results for the periods covered. Certain reclassifications of prior year amounts have been made to conform to current year presentation. These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2003.
NOTE BACCOUNTING CHANGES
In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 143, "Accounting for Asset Retirement Obligations," which requires an entity to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the related long-lived asset. The liability is adjusted to its present value each period and the asset is depreciated over its useful life. A gain or loss may be incurred upon settlement of the liability. SFAS No. 143 was effective for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 on January 1, 2003 resulted in the recognition of an asset retirement obligation of $45 million and a charge of $9 million (net of tax of $5 million), which was included in "Cumulative effect of changes in accounting principles."
In accordance with SFAS No. 143, the Company has recognized asset retirement obligations related to demolition and remediation activities at manufacturing sites in the United States, Germany, France and The Netherlands. In addition, the Company has recognized obligations related to capping activities at landfill sites in the United States, Canada, Italy and Brazil. The aggregate carrying amount of asset retirement obligations recognized by the Company was $47 million at June 30, 2004 and $46 million at December 31, 2003. These obligations are included in the consolidated balance sheets as "Other noncurrent obligations."
In the first quarter of 2003, Dow adopted the fair value provisions of SFAS No. 123, "Accounting for Stock-Based Compensation," for new grants of equity instruments (which include stock options, deferred stock grants, and subscriptions to purchase shares under the Company's Employees' Stock Purchase Plan) to employees. As required by SFAS No. 148, "Accounting for Stock-Based CompensationTransition and Disclosure," the following table provides pro forma results as if the fair value based method had been applied to all outstanding and unvested awards in each period presented:
| |
Three Months Ended |
Six Months Ended |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In millions |
June 30, 2004 |
June 30, 2003 |
June 30, 2004 |
June 30, 2003 |
||||||||||
| Net income, as reported | $ | 685 | $ | 393 | $ | 1,154 | $ | 469 | ||||||
| Add: Stock-based compensation expense included in reported net income, net of tax |
29 | 8 | 52 | 11 | ||||||||||
| Deduct: Total stock-based compensation expense determined using fair value based method for all awards, net of tax |
(34 | ) | (19 | ) | (61 | ) | (38 | ) | ||||||
| Pro forma net income | $ | 680 | $ | 382 | $ | 1,145 | $ | 442 | ||||||
| Earnings per share (in dollars): | ||||||||||||||
| Basicas reported | $ | 0.73 | $ | 0.43 | $ | 1.23 | $ | 0.51 | ||||||
| Basicpro forma | 0.72 | 0.42 | 1.22 | 0.48 | ||||||||||
| Dilutedas reported | 0.72 | 0.43 | 1.22 | 0.51 | ||||||||||
| Dilutedpro forma | 0.72 | 0.41 | 1.21 | 0.48 | ||||||||||